Floatz logo

Parsaclisib

Refractory Diffuse Large B-Cell Lymphoma

Incyte CorporationSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Refractory Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Sun Yat-sen University
Phase 3BBB
Ifosfamide
University of California, Davis
Phase 3BB
Ibrutinib
National Cancer Institute (NCI)
Phase 2BB
Carboplatin
University of California, Davis
Phase 3BB
Polatuzumab Vedotin
Ruijin Hospital
Phase 3BB

View all 16 →

Same molecule, other indications

Parsaclisib is also rated in:

follicular lymphomaDormant
B
Indicative ·
60 / 100
View asset →
marginal zone lymphomaDormant
B
Indicative ·
60 / 100
View asset →
lymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →